Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role: an International Multicenter Retrospective Analysis

NCT04333524 is registered in ClinicalTrials.gov with International Extranodal Lymphoma Study Group (IELSG) as lead sponsor.

NCT NCT04333524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04333524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role: an International Multicenter Retrospective Analysis
Lead sponsor
International Extranodal Lymphoma Study Group (IELSG)
Phase
Observational
Overall status
Active, not recruiting
Start date
December 1, 2020
Completion date
October 15, 2026
Enrollment
496 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

marginal zone lymphoma